Role of IV Calcium to Prevent Diltiazem-related Hypotension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 217 participants.

Also called NCT06494007

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 217 participants (enrolled count) (from the registry)
Sponsor
Haseki Training and Research Hospital (from the registry)
Registry
  • NCT NCT06494007
Other papers using this trial's data
  • Reducing diltiazem-related hypotension in atrial fibrillation: Role of pretreatment intravenous calcium The American journal of emergency medicine, 2025-02 DOI, PubMed 39577214

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Türkiye (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06494007. Randomized; triple masking; primary purpose prevention. Start 2023-01-01 (actual); primary completion 2024-06-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Role of IV Calcium to Prevent Diltiazem-related Hypotension
Acronym
AFstd
Condition
Rapid Ventricular Response
Condition
Hypotension Drug-Induced
Intervention (Drug)
Sodium chloride
Intervention (Drug)
90 mg of calcium
Intervention (Drug)
180 mg Calcium
Lead sponsor
Haseki Training and Research Hospital (class: other)

Record details

Record id
cardio:ct-nct06494007
Content hash
9ece17858f1c7c3e2b15dc0baae286f492a2f3a79d14a97dff9cccb7beb68f64